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n	 INTRODUCTION
Psoriatic arthritis (PsA) is usually con-sidered a benign disease, but this idea 
has been challenged by some recent data. 
Sheeb et al. (1) found there was no signifi-
cant difference in survival between patients 
with PsA and that observed in the general 
population. However, it has recently been 
confirmed that PsA is a chronic inflamma-
tory arthritis and that, like rheumatoid ar-
thritis (RA), it is associated with increased 
cardiovascular mortality (2-4). It has been 
reported that patients with severe psoriasis 
requiring hospitalization have a 50% in-
creased risk of cardiovascular (CV) mortal-
ity (5), which seems to be associated with 
markers of disease activity, such as the pri-
or use of medications, a high erythrocyte 
sedimentation rate (ESR) at presentation, 
and evidence of radiological alterations (3).
Traditional CV risk factors are more com-
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La psoriasi è una malattia autoimmune inﬁ ammatoria cronica della cute geneticamente determinata che coin-
volge il 2-3% della popolazione Caucasica. Diversi pazienti sviluppano una forma di artrite inﬁ ammatoria nota 
con il nome di artrite psoriasica (APs), la cui prevalenza non è ben deﬁ nita. I pazienti affetti da APs hanno un 
tasso di mortalità superiore rispetto alla popolazione generale, e il rischio di mortalità correla con la severità 
della malattia al momento dell’esordio. La disfunzione endoteliale e l’aterosclerosi precoce sono state riportate 
in pazienti affetti da APs che non presentano fattori di rischio per eventi cardiovascolari (CV), tanto che gli 
Esperti ritengono che gli eventi CV rappresentino una causa di mortalità in questi pazienti così come descritto 
nei pazienti affetti da artrite reumatoide (AR). Diversi meccanismi correlati alla malattia potrebbero essere 
coinvolti nello sviluppo del danno vascolare precoce sia nell’APs che nell’AR, quali aumentata sintesi di me-
diatori dell’inﬁ ammazione (quali citochine, chemochine e molecole di adesione), anticorpi contro i componenti 
delle cellule endoteliali, alterazioni dei subsets dei T linfociti, polimorﬁ smi genetici, iperomocisteinemia, stress 
ossidativo, riparazione delle alterazioni vascolari, e fattori iatrogeni. In un recente studio che ha coinvolto 22 
pazienti affetti da APs senza alcun segno o sintomo di malattia CV, è stato osservato che la concentrazione 
della dimetil-arginina asimmetrica (ADMA) è signiﬁ cativamente aumentata nei pazienti affetti da APs rispetto 
ai controlli e che la riserva di ﬂ usso coronarica (RFC) è signiﬁ cativamente ridotta. Inoltre, nei pazienti con 
APs esiste una signiﬁ cativa correlazione tra la RFC e la concentrazione di ADMA nel plasma. La signiﬁ cativa 
correlazione tra la RFC ridotta e il livello di ADMA aumentato suggerisce che, come nei pazienti affetti da 
AR all’esordio, i pazienti affetti da APs soffrano di disfunzione endoteliale e di alterazione del microcircolo 
coronarico. In conclusione, l’APs in fase attiva rappresenta un fattore di rischio per eventi CV, ed è consigliabile 
che i pazienti affetti da APs siano sottoposti a screening per il coinvolgimento CV subclinico e per i suoi fattori 
di rischio.
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mon in patients with PsA than in controls. 
A study from the integrated outcomes data-
base, matched 3,066 PsA patients with oth-
er subjects in a ratio of 1 to 4 on the basis 
of age, gender, location and time in the da-
tabase, and found that the prevalence ratios 
of peripheral cardiovascular disease (CVD) 
(1, 6), cardiovascular heart failure (CHF) 
(1, 5), atherosclerosis (1, 4), ischemic heart 
disease (1, 3), cerebrovascular disease (1, 
3) and hypertension (1, 3) were all higher 
in the patients with PsA. They also found a 
higher prevalence of risk factors for coro-
nary artery disease, such as hypertension 
(1, 3), diabetes (1, 5) and hyperlipidemia 
(1, 2) than in controls (6). Kimhi et al. (7) 
found that PsA patients have thicker com-
mon carotid arteries than healthy controls. 
This correlates with the duration of skin 
and joint disease, spine involvement and 
fibrinogen levels, as well as with conven-
tional risk factors for atherosclerosis, such 
as age, body mass index (BMI), blood 
pressure, and serum glucose levels. 
Increased incidences of diabetes mellitus 
and obesity have been reported in psori-
atic patients (8). PsA and psoriasis patients 
have an altered atherogenic lipid profile (9, 
10) mainly consisting of increased LDL 
sub-fractions and decreased HDL levels. 
Gonzalez-Gay et al. (11) found that there 
is a correlation between serum uric acid 
concentrations and subclinical atheroscle-
rosis in PsA patients without any clinically 
evident CVD.
Gonzalez-Juanatey et al. (12, 13) found 
that patients with PsA without CV risk 
factors or clinically evident CVD show 
endothelial dysfunction and a high preva-
lence of macrovascular disease in the form 
of increased carotid artery intima media 
thickness (IMT) in comparison with ethni-
cally matched controls.
Metabolic syndrome (MS) is made up of 
a group of traditional risk factors that in-
cludes abdominal obesity, atherogenic 
dyslipidemia, hypertension, and insulin 
resistance (14). The presence of MS is a 
strong predictor for type 2 diabetes melli-
tus, stroke, and CV, although controversy 
remains over whether metabolic syndrome 
is a distinct entity and whether the predic-
tive value of the metabolic syndrome for 
CV risk is higher than that expected from 
individual risk factors alone (15).
Recently, a cross-sectional study (16) in-
dicated that MS occurs more frequently in 
patients with PsA than in the general popu-
lation. Among patients with RA, AS (anky-
losing spondylitis), and PsA, PsA patients 
show the highest risk for the presence of 
atherosclerotic risk factors, in particular 
of obesity, impaired glucose tolerance, 
and hypertriglyceridemia, and hence of 
metabolic syndrome. Moreover, the use of 
anti-TNFα treatment was associated with a 
trend towards a lower prevalence of meta-
bolic syndrome supporting the idea that 
persistent inflammation is an aggravating 
factor for atherosclerotic risk (16).
In conclusion, all of these findings dem-
onstrate the potential association between 
PsA and atherosclerotic disease.
n	 CYTOKINES AND PSORIATIC 
 ARTHRITIS 
Various disease-related mechanisms may be 
involved in the development of premature 
vascular damage in patients with PsA or 
RA, including an increased synthesis of pro-
inflammatory mediators (such as cytokines, 
chemokines and adhesion molecules), au-
toantibodies against endothelial cell compo-
nents, perturbations in T-cell subsets, genet-
ic polymorphisms, hyperhomocysteinemia, 
oxidative stress, abnormal vascular repair, 
and iatrogenic factors (17-21).
Pro-inflammatory cytokines are important 
mediators of systemic and local inflamma-
tion, and the abundant expression of inter-
leukin-1 (IL-1) and tumor necrosis factor-α 
(TNFα) has been found in psoriatic skin le-
sions and in the synovial tissue of patients 
with RA or PsA (22). The synovial infil-
trate in both groups of patients is compa-
rable in terms of the number of fibroblast-
like synoviocytes and macrophages, but the 
number of T cells is considerably lower in 
the synovium of patients with PsA, and the 
number of their plasma cells also tends to 
be lower. TNFα, IL-1β, IL-6 and IL-18 ex-
pression is high in both cases (23, 24). 
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TNF is an inflammatory cytokine released 
by activated monocytes, macrophages and 
T lymphocytes that promotes the inflam-
matory responses involved in the patho-
genesis of both RA and PsA (25). It also 
promotes dyslipidemia and insulin resist-
ance, both of which are traditional risk fac-
tors for atherosclerosis; it up-regulates ad-
hesion molecules, leading to the formation 
of fatty streaks and the start of atheroscle-
rosis; and it is involved in inflammation 
leading to plaque rupture (26-28). It may 
also promote thrombophilia, thus encour-
aging thrombotic events. 
In fact, Ingegnoli et al. (29, 30) showed 
increased levels of prothrombin fragment 
1+2 (F1+2) and D-dimer, plasminogen 
activator inhibitor (PAI-1) antigen, PAI-1 
activity and tissue-type plasminogen ac-
tivator (t-PA) antigen in patients with RA 
compared to controls. Moreover, the same 
authors reported a reduction in fibrinoly-
sis inhibition and coagulation biomarkers 
in RA patients after infliximab treatment, 
supporting the hypothesis that anti-TNF 
agents reduce the whole thrombotic risk 
in these patients not only due to cytokine 
inhibition but also due to its effects on co-
agulation (29, 30). 
IL-6 is a pro-inflammatory cytokine that 
stimulates hepatocytes to synthesize acute 
phase response proteins, such as C-reactive 
protein (CRP) and fibrinogen (30). It may 
also contribute to atherosclerosis and arte-
rial thrombosis by enhancing endothelial 
cell adhesiveness, activating the produc-
tion of tissue factor, fibrinogen and factor 
VIII, by increasing platelet production and 
aggregation, and decreasing endogenous 
anticoagulant levels (31).
n	 BIOLOGICAL THERAPY: 
 PSORIATIC ARTHRITIS  
 AND CV INVOLVEMENT
The introduction of the anti-TNFα agents 
infliximab, etanercept and adalimumab 
has dramatically improved the outcome of 
severe RA and also reduced the burden of 
CVD (32). There is compelling evidence 
that TNFα antagonists improve both ax-
ial and peripheral psoriatic arthropathies 
(33), and significantly inhibit radiological 
progression in a sustained manner. They 
also seem to reduce disease-related mor-
tality (20).
Angel et al. (34) showed that anti-TNF 
agents reduce inflammatory activity and 
improve aortic stiffness in patients with 
inflammatory arthritis, thus supporting the 
hypothesis of a favorable anti-inflammato-
ry effect on CV risk in PsA patients. 
A double-blind, placebo-controlled study 
involving 127 patients with PsA showed 
that anti-TNF agents induce a signifi-
cant reduction in concentrations of CRP, 
lipoprotein(a), and homocysteine, and an 
increase in the serum sex hormone-bind-
ing globulin, apolipoprotein (Apo) AI, 
Apo B, and triglycerides; however, the 
study did not confirm the cardioprotective 
effect of anti-TNF agents in this cohort of 
patients (35).
Tocilizumab is a recombinant human-
ized anti-IL6 receptor mAb that prevents 
interactions between IL-6 and the mem-
brane-expressed receptor or its soluble 
counterpart, thus inhibiting IL-6 signal 
transduction (32). Its clinical efficacy has 
been assessed in adult patients with active 
moderate-to-severe RA, including those 
with an inadequate response to TNF antag-
onists, and the current data suggest that its 
tolerability profile is acceptable, infections 
being the most frequently reported adverse 
events. Although RA and PsA are clinical-
ly separate diseases of a different etiology, 
the similarities in the synovial infiltrate 
and increased pro-inflammatory cytokine 
production in PsA support the view that, in 
addition to TNFα blockade, targeted treat-
ments against other pro-inflammatory cy-
tokines such as IL-6 might be effective in 
PsA and co-morbidities such as CVD (36).
n	 PLASMA ASYMMETRIC 
 DIMETHYLARGININE (ADMA)  
 CONCENTRATIONS AND  
 CORONARY FLOW RESERVE 
Plasma asymmetric dimethylarginine 
(ADMA), a major endogenous inhibitor 
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of nitric oxide synthase, is a newly discov-
ered risk factor for endothelial dysfunction 
associated with enhanced atherosclerosis 
(37, 38). 
It has been reported that ADMA is a pre-
dictor of cardiovascular risk (39), and in-
creased plasma ADMA levels have been 
observed in patients with diseases associ-
ated with atherosclerosis, (40) such as hy-
percholesterolemia (41), hypertriglyceri-
demia (42), peripheral arterial disease (43), 
hypertension (44), type 2 diabetes mellitus 
(45), acute coronary syndromes (46, 47) 
and end-stage renal failure (48). We have 
recently found that plasma ADMA levels 
are significantly higher in patients with 
early rheumatoid arthritis (ERA), and that 
this has a statistically significant negative 
effect on coronary flow reserve (CFR), 
which is significantly reduced in ERA pa-
tients without any signs or symptoms of 
coronary artery disease (CAD) (49). 
We previously showed that CFR is re-
duced early in patients with long-standing 
RA without any clinical evidence of heart 
disease, (50) and in a recent study of 22 
PsA patients and 35 healthy controls with 
no history or current signs of CVD, we 
found that ADMA levels were significantly 
higher in the PsA patients (0.71±0.07 vs 
0.48±0.07; p=0.00) who also had a sig-
nificantly reduced CFR (2.86±0.70 vs 
3.3±0.43; p<0.01) (51). Common carotid 
IMT was greater in the PsA patients, but 
the difference was not significant (0.64± 
0.26 vs 0.62 ± 0.5 mm). There was a signif-
icant correlation between CFR and plasma 
ADMA levels in the PsA group (R=0.28; 
p<0.01), but no correlation between plasma 
ADMA levels and IMT (R=0.02; p=0.32), 
the Disease Activity Score 28 (DAS-28) 
(p=0.52) or the Psoriasis Area and Severity 
Index (p=0.98). 
It has recently been demonstrated that CFR 
is a highly sensitive (>90%) diagnostic 
marker of CAD, and that a CFR of less 
than 2 accurately predicts the presence of 
severe (i.e. >70%) coronary stenosis (52). 
The significant correlation between the 
reduced CFR and increased ADMA levels 
in PsA patients may indicate endothelial 
dysfunction and impaired coronary micro-
circulation, as found in patients with early 
RA (49). Kimhi et al. (7) found that PsA 
patients have higher common carotid ar-
tery IMT values than healthy controls and 
the same results were also reported from a 
larger study (53). We also found this in our 
experience, although the difference was 
not statistically significant. This may have 
been due to the relatively small number of 
patients, but it could also indicate that CFR 
(a functional parameter) is a more sensitive 
marker of subclinical atherosclerosis than 
IMT. In a study of 20 patients treated for 
18 months with DMARDs (10 with metho-
trexate and 10 with adalimumab), we found 
that both drugs significantly reduced DAS-
28 (6.0±0.8 vs 2.0±0.7; p<0.0001) and im-
proved CFR (2.4±0.2 vs 2.7±0.5; p<0.01), 
whereas the changes in common carotid 
IMT and plasma ADMA levels were not 
significant (54). In addition to their well-
known anti-phlogistic effects, DMARDs 
improve coronary microcirculation without 
having any direct effect on IMT or ADMA, 
clinical markers of atherosclerosis in pa-
tients with RA and possibly in those with 
PsA (55, 56).
However, Tam et al. (57) in a pilot study 
showed that treatment with anti-TNF 
agents may determine a reduction in IMT in 
PsA patients, associated with improvement 
in inflammatory markers, but independent 
of changes in lipid profiles. Moreover, Ma-
zlan (58) et al. reported a significant asso-
ciation between CV risk and positive IMT 
in PsA patients, although there was no as-
sociation with disease activity, disease se-
verity or DMARD therapy.
 Finally, Di Minno, (59) in a study involv-
ing 224 patients with PsA (120 on TNF-α 
blockers and 104 on DMARDs), reported 
that IMT in PsA patients without CV risk 
was higher than in controls. Furthermore, 
they showed that treatment duration in-
versely predicted IMT in PsA patients on 
TNF blockers but not in those on DMARDs.
In conclusion, all these data indicate that 
active PsA is a risk factor for CVD. PsA 
patients should, therefore, be screened for 
subclinical forms of the disease and its risk 
factors, and an early treatment approach 
should be adopted.
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Psoriasis is a chronic, genetically determined and immunomediated inflammatory skin disease that affects 
2-3% of the Caucasian population. A considerable proportion of these patients develop a form of inflammatory 
arthritis known as psoriatic arthritis (PsA), although the prevalence of this has not been well defined. Patients 
with PsA have a higher mortality rate than the general population and the risk of mortality is related to dis-
ease severity at the time of presentation. Endothelial dysfunction and early atherosclerosis have been found 
in patients with PsA without any cardiovascular disease (CVD) risk factors, and experts believe that CVD is 
one of the leading causes of death, as it is in patients with rheumatoid arthritis (RA). Various disease-related 
mechanisms may be involved in the development of premature vascular damage in both cases, including an 
increased synthesis of proinflammatory mediators (such as cytokines, chemokines and adhesion molecules), 
autoantibodies against endothelial cell components, perturbations in T-cell subsets, genetic polymorphisms, 
hyperhomocysteinemia, oxidative stress, abnormal vascular repair, and iatrogenic factors. In a recent study of 
22 patients with PsA without any signs of CVD, we found that the plasma concentration of asymmetric dimethy-
larginine (ADMA) levels were significantly high and coronary flow reserve (CFR) was significantly reduced. 
Moreover, there was a significant correlation between CFR and plasma ADMA levels in the PsA group. The 
significant correlation between the reduced CRF and increased ADMA levels suggests that, like patients with 
early RA, PsA patients suffer from endothelial dysfunction and impaired coronary microcirculation. Active PsA 
is a risk factor for CVD, and so PsA patients should be screened for subclinical forms of the disease and its risk 
factors, and an early treatment approach should be adopted. 
Parole chiave: artrite psoriasica; coinvolgimento cardiovascolare; dimetil-arginina asimmetrica; fattori di rischio.
Key words: psoriatic arthritis; cardiovascular involvement; asymmetric dimethylarginine; risk factors.
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